Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jochen Vehoff
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
indication for treatment with Gilenya according label
treatment with Gilenya intended
no contraindications for the treatment with Gilanya
all safety-aspects have been fullfilled
age between 18 and 60 years
written consent is given
You may not be if
relapse during the last 30 days befor randomization
steroids within 30 days before randomization
heart rhythm disturbance
new or currently changed dose (last 4 weeks) of bata-blockers, calcium antagonists, antidepressants or antiarrhythmics
diabetes mellitus
polyneuropathy
missing consent
pregnancy
lactation period
Clareo Health | Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
